On May 1, local time, Arvinas and its partner Pfizer jointly announced that the US Food and Drug Administration has approved VEPPANU to treat adult patients with estrogen receptor-positive/human epidermal growth factor receptor 2 negative, advanced estrogen receptor 1 mutation, or metastatic breast cancer, and that patients need to progress after receiving at least one type of endocrine treatment. This is also the first time that the FDA has approved a proteolytic targeting chimera, a heterobifunctional proteolytic agent therapy.

On May 1, local time, Arvinas and its partner Pfizer jointly announced that the US Food and Drug Administration has approved VEPPANU to treat adult patients with estrogen receptor-positive/human epidermal growth factor receptor 2 negative, advanced estrogen receptor 1 mutation, or metastatic breast cancer, and that patients need to progress after receiving at least one type of endocrine treatment. This is also the first time that the FDA has approved a proteolytic targeting chimera, a heterobifunctional proteolytic agent therapy.